The clinical outcome of MPA and Duphaston and Utrogestan in Primed-progesterone ovarian stimulation protocol for advanced endometriosis patients undergoing IVF cycle

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-OIN-16008529

Enrollment

Unknown

Registered

2016-05-24

Start date

2016-05-25

Completion date

Unknown

Last updated

2017-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

HMG+MPA:HMG+MPA

HMG+Duphaston:HMG+Duphaston

HMG+Utrogestan:HMG+Utrogestan

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 20-40y, regular ovulation, FSH less than 10IU/L and AFC 5-20.

Exclusion criteria

Exclusion criteria: ovarian failure, pcos, acute genital tract infection and other systemtic diseases.

Design outcomes

Primary

Measure	Time frame
Number of oocyte retrieval;maturation rate;viable embryo rate;fertilization rate;cleavage rate;implantation rate;clinical pregnancy rate;	—

Secondary

Measure	Time frame
oocyte pick up time;	—

Countries

China

Contacts

Public ContactYanping Kuang

Shanghai Nineth People's Hospital

kuangyanp@126.com+86 021-53078080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026